Climb Bio CLYM
$9.19 −$0.09 (-0.97%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $9.03 -1.76%
Open$8.98
Prev close$9.28
Day range$8.90 – $9.40
Volume770.2K
Market cap$539.80M
P/E (TTM)–
Dividend yield–
CLYM Stock News
Headlines matching Climb Bio or the CLYM ticker, most recent first.
- H.C. Wainwright Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $30 Positive
- Truist Financial Maintains Climb Bio(CLYM.US) With Buy Rating
- A Quick Look at Today's Ratings for Climb Bio(CLYM.US), With a Forecast Between $25 to $40
- B. Riley Securities Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $30 Positive
- RBC Capital Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $23
- Oppenheimer Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $18
- Truist Financial Maintains Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $25
- BTIG Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $20
- RBC Capital Initiates Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $23
- H.C. Wainwright Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $24 Positive
- Wedbush Maintains Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $20
- William Blair Maintains Climb Bio(CLYM.US) With Buy Rating
- Truist Financial Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $25
- Piper Sandler Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $23
- Analysts Offer Insights on Healthcare Companies: Atai Beckley N.V. (ATAI) and Climb Bio (CLYM)
No comments yet — be the first to weigh in on CLYM.
Sign in to join the discussion.